Bevacizumab induced hypertension in gynecologic cancer: Does it resolve after completion of therapy?
Hypertension (HTN) induced by bevacizumab is a side effect that is often thought to resolve after treatment. However, there are currently no reports on rates of resolution. We assess the incidence and timing of the resolution of bevacizumab induced HTN. We evaluated all patients treated with bevaciz...
Saved in:
Main Authors: | Bradley R. Corr (Author), Christopher Breed (Author), Jeanelle Sheeder (Author), Sarah Weisdack (Author), Kian Behbakht (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2016-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impact of blinding interviewers to written applications on ranking of Gynecologic Oncology fellowship applicants from groups underrepresented in medicine
by: Jennifer Haag, et al.
Published: (2022) -
Preparedness of Ob/Gyn residents for fellowship training in gynecologic oncology
by: David W. Doo, et al.
Published: (2015) -
Bevacizumab Dose Affects the Severity of Adverse Events in Gynecologic Malignancies
by: Shu-Ping Lee, et al.
Published: (2019) -
The perceptions of gynecologic oncology fellows on readiness for subspecialty training following OB/GYNRESIDENCY
by: Renata R. Urban, et al.
Published: (2019) -
Bevacizumab (Avegra®) for the treatment of gynecological cancers: joint experience of several centers
by: A. G. Kedrova, et al.
Published: (2021)